2nd World Congress on Targeting Microbiota
Towards Clinical Revolution

Special Session
Fecal Microbiota Transplantation: Practical Issues and Regulation

October 16-17, 2014
Institut Pasteur - Paris, France

www.microbiota-site.com
Dear Colleagues,

It is a pleasure to present you the 2nd World Congress on Targeting Microbiota which will be held at Institut Pasteur, Paris, France on October 16-17, 2014.

Microbiota as the forgotten organ
A large body of evidence show that a diverse population of micro-organisms lives in our skin, mouth, nose, lung and gut, where it plays a strategic role in regulating and possibly controlling human health, well-being, metabolism and diseases.

Microbiotas are maternally transmitted during birth and their composition is influenced by our environment and lifestyle. Intestinal flora is by far the best known microbiota composed of more than 10^14 cells comprising 1000 different species representing a biomass between 1 to 2 kg. Microbiota has probably multiple functions. Its considerable metabolic potential originates from a very high number of genes (the microbiome), which includes unique genes and 150-fold larger coding capacity than the human genome.

The microbiota diversity, its evolutive dynamics and influence on host metabolism open unique opportunities for the identification of new markers of the physiopathological state of each individual. For these reasons, it becomes increasingly important to identify the composition of microbiota and the mechanisms that regulates the host-microbiota crosstalk. Additionally, targeting microbiota with antibiotics, probiotic or even fecal transplants, aiming to alter the microbiota composition, is considered a promising strategy for the development of new solutions for the treatment of disease.

Mitochondria-Microbiota Crosstalk: The Intriguing Relationship
Interestingly, due to the prokaryotic origin of mitochondria, microbiota and mitochondria share commons features. From an evolutionary point of view this common origin may have strongly affected the functional interaction of resident micro-organisms with the host. Moreover, several decades of research on mitochondrial diseases have highlighted a wide and complex spectrum of effects due to mitochondrial impairment, with, however, still unclear links with the nature of affected tissues and organs. Interestingly, the mitochondrial spectrum of diseases for some aspects superimposes on the spectrum of diseases involving the microbiota. Based on these new advances, it becomes important to underscore the mitochondrial – microbiota relationship and possibly consider mitochondria as a particular component of the microbiota. This notion is particularly of interest also for future strategies aiming to the treatment of mitochondrial diseases.

Aims of Targeting Microbiota 2014
✓ Discuss recent advances, implications, impact and perspectives of microbiota on health and diseases.
✓ Research in microbiota is facing important challenges. To date, the most relevant challenge is whether we can modulate and manipulate the human gut microbiota?
✓ How diet, food, antibiotics, hormones, prebiotics and fecal microbiota can affect resident microbiota?
✓ How is microbiota defined in health and disease?
✓ What is the role of microbiota metabolism on host function and disease?
✓ How do microbiota interact with the host and which function(s) microbiota do control and regulate?
✓ Can targeting microbiota prevent or treat inflammation-related diseases, metabolic disorders or CNS diseases?
✓ Do mitochondria and microbiota cross-talk and interact?
✓ How to avoid speculations and marketing on microbiota not supported by actual data?

❖ Among Targeting Microbiota 2014 sessions:
✓ Microbiota and Innovations in 2014: Recent Advances
  o Analysis of Bacterial Species and Metagenome
  o Tools and Innovations
✓ Microbiota, Innovative Methods & Biomarkers: From Predictive to Personalized Medicine
✓ Mitochondria-Microbiota Crosstalk: The Intriguing Relationship
  o The Redox balance and ROS as modulator of host gene expression
  o Microbiota, oxidative stress and Intestinal redox homeostasis
  o Impact of ROS on microbiota quality
✓ The Role of Microbiota in Health and Diseases: The Mechanistic Aspects
✓ New Challenges to Prevent and Treat Metabolic Diseases, Cancer, Liver, Kidney, Lung and Inflammation-Related Diseases
✓ Microbiota and Nutrition: Impact on Bioavailability and Absorption
✓ Microbiota and Longevity: The Missing Link
✓ Microbiota and Brain: Opportunity to Regulate Stress and Depression

❖ Special Session on Fecal Microbiota Transplantation
A workshop on Fecal Microbiota Transplantation will be held on day 2. Fecal microbiota transplantation is a highly effective cure for many pathological conditions, but increased knowledge of the intestinal microbiota in health maintenance, as well as controlled trials of fecal microbiota transplantation in a wide range of disorders are needed before FMT can be accepted and applied clinically. The legal and regulatory aspects will be also discussed.

A Network session will be organized during the 2 days meeting to support exchange and interactions in leading fields linked to microbiota.

Startup and Biotech teams can present their innovations during a dedicated session “10 minutes to convince”.

A discussion will be held between speakers, Scientists and industry sector about Microbiota and medicine of tomorrow.

We hope that you will join us for this dynamic and strategic program and look forward to welcoming you in Paris.

Marvin Edeas  Miria Ricchetti
Chairman of Targeting Mitochondria Task Force Group  Chairman of Local Organizing Committee
Institut Pasteur, Paris
Day 1 - October 16, 2014

07h30 Welcoming & Registration of Attendees
9h00 Introduction Remarks by Chairmen

Session 1: Microbiota 2014: State-of-the-Art & Visions

9h10 Evolution, Cooperation & Conflicts
Pierre-Henri Gouyon, National Museum of Natural History, Paris, France

9h40 Interactions of Segmented Bacterium with the Host Immune System
Nadine Cerf-Bensoussan, Institut Imagine, Paris, France

10h10 Microbiota and Intestinal Epithelium: Decrypting Signals in the Crypt
Philippe Sansonetti, Institut Pasteur, Paris, France

10h40 Break, Posters & Network Sessions

Short Oral Presentations upon abstracts Submission

A single host-derived glycan arbitrates cooperation between host and microbe
Julia Schwartzman, University of Wisconsin, Madison, United States of America

Alignment-free Analysis of Metagenomic Data with Machine Learning: An Alternative Approach for Studying Microbiota
Xuegong Zhang, Tsinghua University, China

Session 2: Microbiota, Innovative Methods & Biomarkers: From Predictive to Personalized Medicine

11h40 – 12h30

Metaproteome Display: A novel approach for biomarker discovery in Inflammatory Bowel Disease
Jonas Zantow, TU Braunschweig, Germany

Strain specific lactobacilli-mediated promotion of host juvenile growth: innovative technique brings new evidence from strains belonging to several lactobacilli species.
Mélanie Mitchell, IGFL, France

A Fast And Inexpensive Flow Cytometry-Based Approach to Analyze the Commensal Microbiota
Jakob Zimmermann, DRFZ Berlin, Germany

Microbiota regulation of fungal infectivity
Melissa Palmieri, University of Perugia, Italy

Gut Microbiota are Related to Parkinson’s Disease and Clinical Phenotype
Filip Schepersjans, Helsinki University Central Hospital, Finland

12h30 Lunch Break, Posters & Network Sessions
Session 3: Mitochondria-Microbiota Crosstalk: The Intriguing Relationship

The Redox balance and ROS as modulator of host gene expression
Microbiota, oxidative stress and intestinal redox homeostasis
Impact of ROS on microbiota quality

14h00 Redox Signaling Mediated by Gut Microbiota: A Mechanism of Host-Symbiont Crosstalk
Andrew Scott Neish, Emory University School of Medicine, Atlanta, USA

14h30 The Enteropathogen Listeria monocytogenes Alters host Cell Mitochondrial Dynamics
Fabrizia Stavru, Institut Pasteur, Paris, France

Session 4: The Microbiota Role in Health & Diseases: The Mechanistic

15h00 Targeted modulation of the gut microbiota-host interaction reveals novel mechanisms involved in host response during obesity
Patrice D. Cani, Louvain Drug Research Institute, Brussels, Belgium

15h30 Break, Posters & Network Sessions

Short Oral Presentations upon abstracts Submission
10 minutes to convince for Biotech & Start-ups teams

Gut Microbiota Modulate Lung Immunity against Mycobacterial Infection
Chuan-Sheng Lin, Chang Gung University, Taiwan, Republic of China

OMNIgene•GUT: A Novel Fecal Self-Collection, Stabilization and Transport System for Gut Microbiome Studies
Carlos Merino, DNA Genotek Inc., Canada

Use of Two NGS Approaches for Studying the Evolution of Skin Microbiota after Application of Exogenous Compounds
Cyrille Jarrin, Libragen, France

18h00 End of First Day

20h30 Dinner between Speakers & Attendees in a French typical Restaurant
If you are interested to take part to this dinner, please register online.

Day 2 - October 17, 2014

Session 5: New Challenges to Prevent & Treat Metabolic Diseases, Cancer, Liver, Kidney, Lung & all Inflammation Related Diseases

9h00 Uncultivated Bacterial Symbionts: A Rich Resource for Drug Development
Joern Piel, ETH Zürich, Zurich, Switzerland

9h30 RORgt + Cells & Symbiotic Microbiota : Regulation of Intestinal immunity
Gerard Eberl, Institut Pasteur, Paris, France

10h00 The new paradigm of tissue microbiota to intestinal immune defense in metabolic disease
Remy Burcelin, INSERM, Toulouse, France

10h30 Break, Posters & Network Sessions

11h00 Modulation of the Anticancer Immune Effects of Cyclophosphamide by the Intestinal Microbiota
Sophie Viaud, Institut Gustave Roussy, Villejuif, France

11h30 Commensal Microbiota as a Trigger of Spontaneous Autoimmune Demyelination
Gurumoorthy Krishnamoorthy, Max Planck Institute of Neurobiology, Munich, Germany

12h00 NOD2-mediated Dysbiosis Predisposition to Transmissible Colitis & Colorectal Cancer
Mathias Chamaillard, Institut Pasteur, Lille, France
Gut microbial profile in patients with Chronic Kidney Disease on conservative treatment: Is there relationship with inflammation and markers of cardiovascular risk?  
Denise Mafra, Federal Fluminense University, Brazil

Inhibition of Hepatic Alcohol Toxicity by Correcting Intestinal Dysbiosis in Mice  
Gladys Ferrere, INSERM, France

Intestinal Dysbiosis Explains Individual Differences In The Susceptibility To Alcoholic Liver Disease  
Gabriel Perlemuter, AP-HP, Antoine-Béclère University Hospital, France

13h00 Lunch Break, Posters & Network Sessions

Host-Bacterial interactions in gut homeostasis and health  
George Grant, University of Aberdeen, United Kingdom

Alterations in Faecal Microbiota of Very-Low-Birth-Weight Neonates after Oral Supplementation with a Mixture of Lactobacillus and Bifidobacterium Strains and their Effects on Rates of Late-Onset Staphylococcus Sepsis  
Piotr B. Heczko, Jagiellonian University Medical College, Poland

Altered Gut Microbial Energy & Metabolism in Children with Non Alcoholic Fatty Liver Diseases  
Sonia Michail, USC and CHLA, USA

Session 6: Microbiota & Brain: Perspectives & Opportunities

14h30 The Microbiome-to-Host Communication Affecting Pregnancy and Fetal Growth in Early Postnatal Life  
Sven Pettersson, Karolinska Institute, Solna, Sweden

15h00 Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour  
John F. Cryan, University College Cork, Cork, Ireland

15h30 Break, Posters & Network Sessions

Session 7: Microbiota, Nutrition & Ageing  
16h00 – 16h40

D-Fagomine balances gut Bacteroidales and reduces weight gain in rats fed a high-fat high-sucrose diet  
Sara Ramos-Romero, Institute for Advanced Chemistry of Catalonia, Spanish Research Council (CSIC), Spain

Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia  
Laure Bindels, Université Catholique de Louvain, Belgium

Polyphenols and a Lectin-Limited Diet Promote Weight Loss By Altering the Human Gut Microbiome  
Steven Robert Gundry, The Center for Restorative Medicine, United States of America

The Microbiota of the Long Living Naked Mole Rat  
Gerd Birkenmeier, University of Leipzig, Germany

Special Session on Fecal Microbiota Transplantation: Practical Issues & Regulation

The aim of this special session is to discuss the last advances, practical issues, limits of the intestinal microbiota and Fecal microbiota transplantation in various pathologies.

16h40 Variation in bacterial community stability after fecal microbiota transplantation  
David Berry, University of Vienna, Vienna, Austria
Alterations of Fecal Microbiota and Metabolic Landscape in Response to Oral or Intravenous Iron Replacement Therapy in Patients with Inflammatory Bowel Diseases
Annemarie Schmidt, Technische Universität München, Germany

Transplantation of Genetically and Diet-induced Obese Gut Microbiota in Conventional Mice Blunts High-Fat Diet-induced Glucose Homeostasis Imbalance
Matteo Serino, INSERM UMR1048-I2MC, France

Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in a Child via a Percutaneous Gastrojejunostomy
Xavier Stephenne, Université Catholique de Louvain-Cliniques universitaires St Luc, Belgium

Juristical Hurdles and Possibilities for Companies providing Faecal Transplant Services
Andreas Schwiertz, SymbioVaccin GmbH, Germany

18h00  Discussion & Conclusion of Targeting Microbiota 2014

Targeting Microbiota 2014 Awards:
- Scientific Contribution Award 2014
- Young Scientific Contribution for Oral and Poster Contribution

18h30  End of Targeting Microbiota 2014

For all request concerning demonstrations, exhibition and general information, please contact:

Targeting Microbiota 2014
Institut Pasteur
25-28 rue de la Paix
75015 Paris
www.microbiota-site.com
Microbiota@microbiota-site.com